{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:48Z","timestamp":1782337308616,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clml.2024.07.020","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T18:44:31Z","timestamp":1722710671000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies"],"prefix":"10.1016","volume":"25","author":[{"given":"Utkarsh","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrima","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2024.07.020_bib0001","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ajh.27075","article-title":"2024 update: advances in the risk stratification and management of large B-cell lymphoma","volume":"98","author":"Tavakkoli","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.07.020_bib0002","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d'etudes des lymphomes de l'adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.07.020_bib0003","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.07.020_bib0004","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2024.07.020_bib0005","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"10.1016\/j.clml.2024.07.020_bib0006","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.07.020_bib0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.07.020_bib0008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-Cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.clml.2024.07.020_bib0009","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet North Am Ed"},{"issue":"14","key":"10.1016\/j.clml.2024.07.020_bib0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.020_bib0011","article-title":"Management considerations for patients with primary refractory and early relapsed diffuse large B-Cell lymphoma","volume":"43","author":"Duarte","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1016\/j.clml.2024.07.020_bib0012","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.07.020_bib0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2024.07.020_bib0014","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: eastern cooperative oncology group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.07.020_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.07.020_bib0016","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.07.020_bib0017","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.07.020_bib0018","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-Cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2024.07.020_bib0019","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.07.020_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2023-180952","article-title":"Lisocabtagene maraleucel as second-line therapy for R\/R large B-Cell lymphoma in patients not intended for hematopoietic stem cell transplant: final analysis of the phase 2 pilot study","volume":"142","author":"Sehgal","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.07.020_bib0021","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.07.020_bib0022","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.020_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.07.020_bib0024","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2024.07.020_bib0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.07.020_bib0026","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.07.020_bib0027","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent cd20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.07.020_bib0028","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.07.020_bib0029","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large b-cell lymphoma: the orcharrd study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.07.020_bib0030","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/bloodadvances.2022008294","article-title":"Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy","volume":"7","author":"Wudhikarn","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2024.07.020_bib0031","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.07.020_bib0032","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-024-01084-w","article-title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","volume":"14","author":"Shadman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.clml.2024.07.020_bib0033","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2024.07.020_bib0034","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","article-title":"A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL","volume":"131","author":"Sauter","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.07.020_bib0035","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2022-165699","article-title":"Polatuzumab vedotin combined with r-ice (polar-ice) as second-line therapy in relapsed\/refractory diffuse large b-cell lymphoma","volume":"140","author":"Herrera","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.07.020_bib0036","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous epcoritamab + r-dhax\/c in patients with relapsed or refractory diffuse large b-cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results","volume":"140","author":"Abrisqueta","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.020_bib0037","unstructured":"Clinicaltrials.gov. a study evaluating the efficacy, safety, and pharmacokinetics of glofitamab in combination with rituximab plus ifosfamide, carboplatin etoposide phosphate in participants with relapsed\/refractory transplant or car-t therapy eligible diffuse b-cell lymphoma. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05364424?term=NCT05364424&rank=1."},{"issue":"1","key":"10.1016\/j.clml.2024.07.020_bib0038","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.clml.2024.07.020_bib0039","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.clml.2024.07.020_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.07.020_bib0041","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor t-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10.1016\/j.clml.2024.07.020_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.08.010","article-title":"The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large b-cell lymphoma in the United States: an economic evaluation of the zuma-7 trial","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2024.07.020_bib0043","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.7326\/M22-2276","article-title":"Second-line chimeric antigen receptor t-cell therapy in diffuse large b-cell lymphoma : a cost-effectiveness analysis","volume":"176","author":"Kelkar","year":"2023","journal-title":"Ann Intern Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:39:35Z","timestamp":1772606375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2152265024002891"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}